D. Eaton

382 Phase II antitumor activity of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in patients with sarcoma enrolled in a randomized discontinuation study

M. Ratain, I. Judson, A. Patnaik, 2004 .

Clinical Benefit of New Targeted Agents in Phase I Trials in Patients with Advanced Colorectal Cancer

I. Judson, S. Kaye, H. Arkenau, 2009, Oncology.

Identification of factors limiting patient recruitment into phase I trials: a study from the Royal Marsden Hospital.

I. Judson, S. Kaye, S. Stapleton, 2008, European journal of cancer.

A phase I study of the nitroimidazole hypoxia marker SR4554 using 19F magnetic resonance spectroscopy

M O Leach, I Judson, M Tracy, 2009, British Journal of Cancer.